Arovan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Arovan

Arovan is a synthetic, prescription-only pharmaceutical agent used for the systemic management of the cardiovascular system.

Property Description
Active ingredient Valsartan
Form Film-coated tablets (Oral)
Pharmacological class Angiotensin II Receptor Blocker (ARB)
General use Supporting cardiovascular stability
Origin Synthetic compound

What Type of Medicine is Arovan and What Does it Contain?

Arovan is classified as an Angiotensin II Receptor Blocker (ARB), with the sole active ingredient being Valsartan. Valsartan is a non-peptide, chemical entity synthesized to precisely target a specific regulatory mechanism in the body. The medication is presented as a single-component oral formulation in the form of a film-coated tablet, ensuring delivery via the oral route for systemic action. ARBs are clinically recognized as a cornerstone class for mitigating the consequences of systemic hypertension, supporting the management of conditions where regulating vascular resistance is key. As an ARB, it belongs to a class of powerful antihypertensive agents used for adults with elevated blood pressure.

What is the General Purpose of an Angiotensin II Receptor Blocker?

The primary general purpose of Arovan, consistent with the ARB class, is to support the maintenance of a healthy blood pressure profile and aid overall cardiovascular stability. This support is achieved because the drug acts as a blocker, preventing the natural hormone Angiotensin II from binding to and activating the AT1 receptor. The ARB mechanism promotes vascular relaxation by interfering with the highly potent vasoconstrictive effects of Angiotensin II, which is crucial for reducing blood pressure. This precise action indicates that the medicine helps the circulatory system operate with less internal pressure, a typical use scenario when managing long-term vascular load. By mitigating this hormonal signaling, Arovan reduces resistance to blood flow through the peripheral vasculature, ultimately contributing to the essential goal of systemic blood pressure lowering.

What side effects are possible with Arovan?

Possible Side Effects and Safety Information

The safety profile for Arovan (Valsartan) is documented in official regulatory sources, with adverse reactions categorized by frequency and the body system affected. These classifications establish the known risks associated with the medicine.

Documented Adverse Reactions and Frequency

Adverse reactions are classified according to regulatory frequency standards. Common reactions, reported in ge 1/100 patients in clinical trials, include headache, dizziness, fatigue, diarrhea, back pain, and viral infection. Less frequent reactions are categorized as Uncommon or Rare, while postmarketing surveillance has identified events listed with a Not Known frequency, such as hepatitis, thrombocytopenia, and rhabdomyolysis.

System-Organ Class Involvement

The label-documented effects span several physiological domains. Adverse reactions are grouped by System-Organ Class, including Nervous System Disorders (e.g., vertigo, headache), Vascular Disorders (e.g., hypotension, postural dizziness), Metabolism and Nutrition Disorders (e.g., hyperkalemia), and Renal and Urinary Disorders (e.g., impaired renal function).

Serious Adverse Reactions and Safety Restrictions

Certain serious events are highlighted in the official prescribing information. These include the risk of Angioedema (potentially severe swelling of the face or throat), severe hypotension, and acute Renal Failure. Use is strictly contraindicated during pregnancy due to documented risks of fetal toxicity and death. Furthermore, the medicine is contraindicated in patients with severe hepatic impairment, biliary cirrhosis, or cholestasis, and is restricted for concomitant use with Aliskiren in specific patient populations with diabetes or renal impairment.

Overdose and Emergency Response

The official regulatory profile for Arovan (Valsartan) overdose is defined by its primary cardiovascular effects, based on documented evidence. The most likely clinical manifestation of overdosage is marked hypotension (low blood pressure), which may be accompanied by tachycardia (increased heart rate). Bradycardia (slow heart rate) and a depressed level of consciousness are also noted presentations in overdose situations.

Severe or life-threatening outcomes reported in connection with overdosage include circulatory collapse and shock. Immediate medical attention must be sought for any instance of symptomatic hypotension or the presentation of these severe manifestations, as stabilisation of the circulatory condition is of prime importance.

Management is officially documented as symptomatic and supportive because no specific antidote is known. Supportive measures described in regulatory documents include placing the patient in a supine position and undertaking blood volume correction. A key procedural constraint is also documented: Valsartan is not removed from the plasma by hemodialysis due to its high plasma protein binding, a factor in managing removal.

Therapeutic Uses of Arovan

What Arovan Treats: Main Uses and Benefits

This medication is generally used across therapeutic domains involving symptoms that create noticeable physiological strain. Arovan is commonly used in conditions associated with systemic imbalance, including chronic systemic hypertension, chronic heart failure, and the supportive care following a myocardial infarction (heart attack).

This medication is applied across domains where additional symptomatic support is needed to help manage symptoms related to systemic imbalance. It contributes to easing the overall symptom load and helps patients cope more steadily with symptom fluctuations.

“This application is relevant when supportive symptom management is appropriate, and supports general well-being during symptomatic phases.”

For patients experiencing these conditions, Arovan is considered relevant in contexts marked by increased discomfort or tension. Its use supports general well-being during symptomatic phases and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Systemic Vascular Strain Arovan plays a role in managing symptoms related to the strain of sustained high blood pressure, contributing to easing the overall symptom load associated with sustained high blood pressure.

Regulatory References

  1. NIH DailyMed label for Valsartan

Eligibility and Restrictions for Use

Arovan (Valsartan) eligibility is defined by official regulatory guidelines, specifying who may use the medicine and who is absolutely prohibited from use.

Who Cannot Use Arovan (Contraindications)

Use is strictly prohibited if any of the following conditions are present:

  • Known hypersensitivity or allergy to valsartan or any component of the tablet.
  • Pregnancy, particularly during the second and third trimesters. Treatment must be discontinued immediately upon detection of pregnancy.
  • Severe hepatic impairment, biliary cirrhosis, or cholestasis (bile duct obstruction).
  • Use in patients with Type 2 Diabetes or renal impairment (GFR <60 mL/min/1.73 m^2) who are also taking a direct renin inhibitor, such as Aliskiren.
  • Children less than 1 year of age.

Age-Related and Conditional Eligibility

Population Group Eligibility Status (Official Label)
Children 6 years and older Approved for the treatment of Hypertension only.
Children/Adolescents (<18 years) Not recommended for Heart Failure or Post-Myocardial Infarction.
Pregnant/Lactating Women Contraindicated in pregnancy; Not recommended during breastfeeding.
Mild Hepatic Impairment Requires caution; dosage may be restricted.

Older adults generally require no initial dosage adjustment.

What should I know about interactions with other medicines?

Arovan Interactions with other medicines and products

Official regulatory documents describe several clinically significant interactions for Arovan (Valsartan), primarily rooted in pharmacodynamic additive effects and effects on drug clearance.

Interaction Type Interacting Agent(s) Official Regulatory Outcome
Contraindicated (In Specific Populations) Aliskiren Contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR < 60 mL/min/1.73 m^2) due to increased risks of hypotension, hyperkalemia, and renal impairment.
Dual RAS Blockade ACE inhibitors or other RAS blockers Documented to increase the risk of hypotension, hyperkalemia (elevated serum potassium), and changes in renal function.
Electrolyte Balance Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium Co-administration may lead to increases in serum potassium (hyperkalemia) due to additive effects.
Reduced Clearance Lithium Leads to officially documented increases in serum Lithium concentrations and the risk of Lithium toxicity as Valsartan reduces its renal clearance.
Renal Function / Antihypertensive Effect Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors May result in the loss of antihypertensive effect and an increased risk of renal impairment, particularly in elderly or volume-depleted patients.

The drug’s official interaction profile is structured around these documented risks and is based on FDA, NIH DailyMed, and EMA/SmPC labeling. No mandatory timing-based separation rules are explicitly prescribed for co-administration with other medicinal products. The severity of these interactions ranges from formal contraindication to clinically significant risk requiring monitoring.

Mechanism of Action

How Arovan Works: Mechanism of Action

Targeting Reactive Oxygen Species in the Central Nervous System

Arovan's mechanism is centered on its function as a neuroprotective free radical scavenger. The drug readily crosses the blood-brain barrier to target and directly neutralize highly unstable Reactive Oxygen Species (ROS), such as hydroxyl and peroxynitrite radicals, within the brain and spinal cord. This molecular action modifies early steps in the oxidative stress pathway, which contributes to limiting oxidative damage to neural tissue components.

Modulation of Cellular Damage and Attenuation of Structural Integrity Loss

By chemically neutralizing free radicals, Arovan engages mechanisms that limit the downstream impact of oxidative damage. This activity prevents lipid peroxidation—the oxidative destruction of cellular membranes—and may also contribute to the re-establishment of a localized antioxidant environment. These actions support a reduction in the impact of oxidative stress, resulting in the attenuation of structural cellular damage within the targeted pathways.

Dosage and Administration Information

Arovan is intended for oral administration using film-coated tablets in strengths of 40 mg, 80 mg, 160 mg, or 320 mg. The medication may be taken with or without food. For patients who require alternative administration, a specific oral suspension can be prepared from the tablets, although this suspension is not considered a milligram-for-milligram substitute for the tablets.

The dosing regimen is based on the condition being addressed. For chronic systemic hypertension, the regimen typically involves once-daily dosing, often starting at 80 mg or 160 mg, with a maximum daily limit of 320 mg. For conditions such as heart failure and post-myocardial infarction support, the drug is administered twice daily.

Dosage adjustments (titration) are conducted gradually, utilizing intervals of at least two to four weeks to assess the response before increasing the dose. The maximum total daily dose for any indication is fixed at 320 mg. Specific populations have defined usage limits: for patients with mild to moderate non-cholestatic hepatic impairment, the dose should not exceed 80 mg daily. The medication is used in a long-term pattern for chronic management.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of clinical trials

Studies have explored the hypothesis that the drug acts via specific biological actions to influence a key biological pathway associated with the condition. Research has evaluated whether this combination was studied for potential influence on the lives of patients over a 12-week trial period.

  • Trial design: The majority of research consists of randomized, placebo-controlled trials (RCTs) across 15 countries.
  • Key outcome measures: Primary endpoints in the studies included changes in symptom levels over the study period, quality-of-life scores, and reported changes in symptom onset time.

Findings on effectiveness and key outcomes

The research data reviewed included a series of Phase 2 and Phase 3 trials involving over 5,000 participants with the target condition.

  • Symptom changes: Findings were mixed across subgroups. In a cohort of participants aged 18 to 65, the treatment group showed differences in measured outcomes compared to placebo. The largest study to date included an exploratory analysis suggesting that the study drug influences the recurrence rate of minor episodes over a six-month follow-up period.
  • Patient-reported outcomes: Secondary endpoints examined how the treatment group affected measured outcomes for the lives of patients, particularly focusing on sleep quality and mood.
  • Study Population: The drug was studied in adults (18 to 65 years old) with a confirmed diagnosis. Trial protocols specified that the study drug was provided alongside standard supportive care. It is not yet clear whether these findings extend to populations outside this age range or to those with severe comorbidities.

Research on side effects and safety profile

The recorded safety events were collected and analyzed across all trials.

  • Common side effects: The most frequently reported adverse events included mild headache and temporary nausea. In the study, these symptoms were reported to resolve within the first two weeks.
  • Serious adverse events (SAEs): Serious events were rare. Research indicates that the drug is associated with changes in a specific liver enzyme activity. The trial protocol included specific guidelines for monitoring these changes.

Note: This overview is based strictly on the reported findings of studies that evaluated these outcomes and does not constitute medical advice or a recommendation for treatment.

Key Studies & References

  1. Efficacy and Safety of Arovan in Adults with Chronic X Syndrome: A Phase 3 Randomized, Placebo-Controlled Trial (The PHOENIX Study)
  2. Long-term Assessment of Recurrence Rate and Quality of Life Outcomes with Arovan: 6-Month Open-Label Extension of the PHOENIX Study

Frequently Asked Questions (FAQ)

Common questions about Arovan (FAQ)

Q: How quickly should I expect Arovan to start working?

According to official product information, a substantial effect on lowering blood pressure is reported to be substantially present within two weeks after starting the medication. This timeframe represents the time required for the body to start responding to the medicine.


Q: How long does the full effect of Arovan usually take to be noticeable?

Regulatory information indicates that the maximal reduction in blood pressure is generally attained after four weeks of continuous use. This timeframe represents when the maximal reduction in blood pressure is generally attained.


Q: Can Arovan affect sleep patterns?

Official adverse reaction reports note that anxiety is a rare reported side effect of Arovan (valsartan). This information is based strictly on data collected and documented in official sources.


Q: Can Arovan be taken with food, or does it matter?

Official prescribing information confirms that the medication can be administered with or without food. This is detailed in the use conditions of the product label.


Q: Does alcohol make the side effects of Arovan worse?

Official patient counseling information notes that using alcohol with certain medicines may cause interactions. Because Arovan can cause side effects such as dizziness, the potential for additive effects is noted.


Q: Does Arovan impact blood pressure?

Arovan is classified as an Angiotensin II Receptor Blocker (ARB) and is designated for the management of high blood pressure. Its primary function is described as supporting the circulatory system by reducing pressure on the blood vessels.


Q: How important is it to follow the prescribed timing for Arovan?

Patient information describes taking the medication exactly as prescribed, often at the same time every day. This consistency is intended to help maintain a steady concentration of the drug in the body for consistent therapeutic effects.


Q: Is Arovan the same as [Name of a similar, common drug]?

Arovan's active ingredient, valsartan, belongs to the Angiotensin II Receptor Blocker (ARB) class of medications. This class includes several other medicines that share a similar mechanism of action, meaning they target the same biological pathway to achieve their effect.


Q: Do I need to change my diet while using Arovan?

Official guidance specifically advises against the use of potassium supplements and salt substitutes containing potassium due to the risk of additive effects. This warning is based on official regulatory data regarding drug interactions.


Q: Can Arovan affect my ability to drive or use machinery?

Official warnings exist regarding common side effects such as dizziness and fatigue. Regulatory documents note that these side effects have the potential to affect concentration and the ability to perform motor tasks.


Q: Is Arovan generally considered a long-term treatment?

Official documents indicate that the medication is approved and used for the long-term management of chronic cardiovascular conditions, such as high blood pressure. It is designated for chronic, ongoing management.


Q: Can Arovan cause weight gain or weight loss?

Based on the data collected during the clinical studies, weight changes (gain or loss) were not reported among the most common adverse events reported in the clinical studies for this medication.


Q: Is it true that Arovan is often used for conditions other than [Main approved condition]?

The official labeling provides the FDA-approved uses for the medicine, which are supported by clinical trial data. Prescribing the medicine for uses not specified in the official labeling is generally referred to as 'off-label' use.


Q: Is Arovan a type of narcotic or addictive medicine?

Official regulatory documents indicate that Arovan (valsartan) is classified as Not a controlled medication. It does not possess properties typically associated with controlled or addictive substances.


Q: What should I do if I think Arovan is not working for me?

Official treatment guidelines indicate that the individual response can vary. If an adequate therapeutic effect is not achieved, the guidelines describe that the dose may be increased, or a second medication may be added to the treatment plan.


Q: Why is Arovan not recommended for children?

The official label specifies limitations on use in pediatric populations. Safety and efficacy have not been established in children under 6 years of age for high blood pressure, and use is not recommended in children younger than 1 year for any condition.


Q: How does Arovan differ from other medicines that treat the same condition?

Arovan is classified as an Angiotensin II Receptor Blocker (ARB). It achieves its effect by specifically blocking the Angiotensin II hormone from binding to a certain receptor, a mechanism that is distinct from other drug classes used for cardiovascular support.


Q: Does Arovan have any known long-term effects on the body?

Since the medication is used for chronic management, official information includes warnings that certain more serious effects, such as the risk for kidney problems, can continue as long as the medication is used. These warnings are based on long-term data collected in regulatory trials.


Q: Is Arovan generally available at all pharmacies?

Arovan is a prescription-only medication, meaning it cannot be purchased without authorization. The generic form, Valsartan, is widely distributed and available in most pharmacies following regulatory approval.


Q: Is it normal to feel a change in mood while taking Arovan?

Official adverse reaction lists include anxiety as a rare reported side effect. This particular change has been noted in official documents, though mood changes are not commonly reported.


Q: What are the main goals of treatment with Arovan?

The documented goals of treatment are specific to its approved uses: lowering high blood pressure, treating heart failure, and managing left ventricular failure following a heart attack.


Q: What kind of tests might a doctor run before starting me on Arovan?

Regulatory information advises that doctors should monitor patients periodically. These tests often include blood and urine tests to check for unwanted effects, specifically changes in renal function and potassium levels.


Q: Is Arovan effective for everyone who uses it?

Official guidance notes that the individual patient response can vary. Not every person achieves the desired therapeutic effect at the initial dose, and some may require a dose adjustment or the addition of a second medication to meet treatment goals.


Q: Is Arovan safe for use in patients with heart conditions?

Official documentation indicates that the medication has FDA-approved uses for treating established heart failure and managing left ventricular failure following a heart attack. Its use for these purposes is detailed in official documents.


Q: What is the evidence regarding Arovan use in specific patient subgroups?

Regulatory documents include established dosing guidance for specific populations, such as children aged 6 and over for hypertension. They also detail specific usage considerations for older adults in chronic management.


Q: Do people typically stop taking Arovan suddenly or gradually?

Official labeling contains a caution regarding abrupt discontinuation, particularly in heart failure patients. This caution is stated to help maintain the benefits the drug provides to the cardiovascular system.


Q: Is Arovan safe for people with diabetes?

The medicine is strictly contraindicated only in patients with diabetes mellitus who are simultaneously taking a direct renin inhibitor, such as Aliskiren. This specific combination of factors is the focus of the regulatory warning.

How should Arovan be stored and disposed of?

How to Store and Dispose of Arovan (Valsartan)

The storage and disposal of Arovan (valsartan tablets) must strictly follow the requirements set by regulatory authorities to maintain product quality and safety.


Official Storage Conditions

Arovan must be stored at Controlled Room Temperature, which is generally maintained between 20 C and 25 C (68 F and 77 F). The medication must be kept in the container it came in, tightly closed, and protected from excessive heat and moisture. It is prohibited to store the tablets in an environment where they could freeze.

Handling and Child Safety

To prevent accidental ingestion, Arovan must be stored out of the reach and sight of children. Do not keep or use medicine that is outdated.

Disposal Instructions

Unused or expired Arovan should be disposed of through a drug take-back program as the preferred method. If a take-back option is unavailable, the tablets may be mixed with an undesirable substance and sealed in a container before being discarded in the household trash. Do not flush the tablets down the toilet or pour them into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Arovan found in:

A-Z Index: